title: Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans.
abstract: This study examined D-amphetamine (D-AMPH)-induced displacements of [18F] fallypride in striatal and extrastriatal regions and the correlations of these displacements with cognition, affect, and sensation-seeking behavior. In all, 14 normal subjects, six females and eight males (ages 21-32, mean age 25.9 years), underwent positron emission tomography (PET) with [18F]fallypride before and 3 h after a 0.43 mg/kg oral dose of D-AMPH. Levels of dopamine (DA) D2 receptor density were calculated with the reference region method of Lammerstma. Percent displacements in striatal and extrastriatal regions were calculated for the caudate, putamen, ventral striatum, medial thalamus, amygdala, substantia nigra, and temporal cortex. Correlations of changes in cognition, affect, and sensation seeking with parametric images of D-AMPH-induced DA release were computed. Significant displacements were seen in the caudate, putamen, ventral striatum substantia nigra, and temporal cortex with a trend level change in the amygdala. Greatest displacements were seen in striatal subdivisions-5.6% in caudate, 11.2% in putamen, 7.2% in ventral striatum, and 6.6% in substantia nigra. Lesser decrements were seen in amygdala-4.4%, temporal cortex-3.7%, and thalamus-2.8%. Significant clusters of correlations of regional DA release with cognition and sensation-seeking behavior were observed. The current study demonstrates that [18F]fallypride PET studies using oral D-AMPH (0.43 mg/kg) can be used to study D-AMPH-induced DA release in the striatal and extrastriatal regions in humans, and their relationship with cognition and sensation-seeking behavior.
authors.affiliation: Department of Radiology, Vanderbilt University, Nashville, TN 37232-2675, USA.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Riccardi
authors.forename: Rui
authors.initials: R
authors.lastname: Li
authors.forename: Mohammad Sib
authors.initials: MS
authors.lastname: Ansari
authors.forename: David
authors.initials: D
authors.lastname: Zald
authors.forename: Sohee
authors.initials: S
authors.lastname: Park
authors.forename: Benoit
authors.initials: B
authors.lastname: Dawant
authors.forename: Sharlet
authors.initials: S
authors.lastname: Anderson
authors.forename: Mikisha
authors.initials: M
authors.lastname: Doop
authors.forename: Neil
authors.initials: N
authors.lastname: Woodward
authors.forename: Evan
authors.initials: E
authors.lastname: Schoenberg
authors.forename: Dennis
authors.initials: D
authors.lastname: Schmidt
authors.forename: Ronald
authors.initials: R
authors.lastname: Baldwin
authors.forename: Robert
authors.initials: R
authors.lastname: Kessler
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000661:Amphetamine / Q000494:pharmacology*; D000679:Amygdala / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D001479:Basal Ganglia / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D001549:Benzamides / Q000378:metabolism*; D001667:Binding, Competitive / Q000187:drug effects / Q000502:physiology; D001931:Brain Mapping; D003071:Cognition / Q000187:drug effects / Q000502:physiology; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D004644:Emotions / Q000187:drug effects / Q000502:physiology; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D011759:Pyrrolidines / Q000378:metabolism*; D011877:Radionuclide Imaging; D017448:Receptors, Dopamine D2 / Q000819:agonists* / Q000378:metabolism; D013378:Substantia Nigra / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
chemical_list: D001549:Benzamides; D018765:Dopamine Uptake Inhibitors; C094948:N-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D000661:Amphetamine; D004298:Dopamine